Narcan Nasal Spray (naloxone hydrochloride), a product of pharmaceutical company Adapt Pharma Limited, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of opioid overdose.
Naloxone has been used to treat opioid overdose for more than four decades, but before the approval of Narcan, it was administered only via injection. Narcan comes in a ready-to-use, four-milligram dose that can be administered before help arrives for an overdose or suspected overdose.
In an effort to keep Narcan affordable, Adapt Pharma offers it at $37.50 per dose for first responders, colleges, firefighters and other groups that want to have it on hand.
"We are delighted to have reached agreement with the Clinton Health Matters Initiative, an initiative of the Clinton Foundation, our first partner in establishing this discounted Public Interest Price approach," Rain Henderson, CEO of the Clinton Health Matters Initiative, said. "The Clinton Health Matters Initiative is committed to efforts to reduce opioid overdose deaths, including by making naloxone more widely available. We believe that the partnership and pricing agreement with Adapt will assist us in helping organizations across the U.S. to save lives by making naloxone more affordable and accessible for those who need it most."
More information about Narcan is available online at www.NarcanNasalSpray.com.
